Related references
Note: Only part of the references are listed.Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey et al.
AAPS JOURNAL (2021)
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Reid W. Merryman et al.
LEUKEMIA (2021)
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Naval Daver et al.
LEUKEMIA (2021)
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
Kapil Saxena et al.
CANCER (2021)
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Joshua F. Zeidner et al.
BLOOD CANCER DISCOVERY (2021)
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
Betul Oran et al.
CANCER (2020)
Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Lu Tang et al.
CLINICAL CANCER RESEARCH (2020)
Immune Checkpoint Inhibitors in AML-A New Frontier
Rohit Thummalapalli et al.
CURRENT CANCER DRUG TARGETS (2020)
Expression patterns of immune checkpoints in acute myeloid leukemia
Cunte Chen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation
Awais Ijaz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
Farhad Ravandi et al.
LANCET HAEMATOLOGY (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Clinical Development of PD-1 Blockade in Hematologic Malignancies
Matthew J. Pianko et al.
CANCER JOURNAL (2018)
Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide
Laura K. Schoch et al.
BLOOD ADVANCES (2018)